Search results for: NICE
Filter search results
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
1 March 2019
…between health outcomes and health expenditures in England. Results suggest that setting a cost-effectiveness criterion for NICE may not be capable of being synthesised using scientific methods alone, but involve…
Dr. Jacoline Bouvy
19 March 2024
…produced by NICE’s Technology Appraisals and Highly Specialised Technologies work programmes. Prior to joining NICE, Jacoline worked at the European Medicines Agency as a National Expert in the Pharmacovigilance Department….
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
…that can boost user confidence and uptake. Enabler: There needs to be flexibility in value assessments of digital health technologies (DHT) similar to the NICE 2022 guidance of different appraisal…
Meindert Boysen
13 March 2025
…was director of the health technology evaluation programmes at the National Institute for Health and Care Excellence (NICE), and deputy Chief Executive Officer. In his role as director, Meindert was…
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
…used by England’s National Institute for Health and Care Excellence (NICE). CDA-AMC’s processes also differ from NICE’s in terms of committees’ explicit consideration of feasibility (especially infrastructure needs and affordability)…
How long are patients WAITing for new treatments?
2 July 2026
…the rate, extent, and speed of availability requires careful interpretation. England illustrates the point: the accessibility date for a NICE-approved medicine is governed by the NHS funding directive, which gives local…
OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme
10 December 2014
…for prioritising access to it “will continue to undermine NICE, duplicate effort, and distort allocation of NHS resources while failing to support the development of cost effective drugs from which…
OHE at ISPOR Philadelphia: Presentations and Posters
4 June 2015
…large prevalence diseases? Lessons from hepatitis C – Adrian Towse’s slides Early access to medicines: What is in it for payers? – Adrian Towse’s slides An Analysis of NICE ‘Recommended…
OHE Lunchtime Seminar on 14 December 2015: From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers
13 November 2015
…decision-making criteria employed by health technology assessment (HTA) agencies differs between countries. Specifically, while the National Institute for Health and Care Excellence (NICE), the Australian Pharmaceutical Benefits Advisory Committee (PBAC)…